Skip to main content

Table 3 Characteristics of patients who met 80/80/80 rule and were candidate for propensity score matching

From: Multicenter comparison of PEG-IFN α2a or α2b plus ribavirin for treatment-naïve HCV patient in Korean population

Patients who met Total PEG-IFN alfa-2a PEG-IFN alfa- 2b P*
80/80/80 rule     
Genotype 1, n (%) 286 171 (59.8) 115 (40.2) 0.45
 Age, years 49 ± 11 48 ± 11 49 ± 11 0.52
 BMI (Kg/m2) 24.6 ± 3.1 24.8 ± 3.2 24.3 ± 2.9 0.29
 ALT (IU/L) 100 ± 81 103 ± 80 97 ± 84 0.51
 HCV RNA (IU/mL) 3.7×106±1.6×106 2.4×106±1.5×106 5.6×106±2.2×106 0.15
 F3-4 Fibrosis stage, n (%) § 29/94 (30.9) 26/75 (34.7) 3/19 (15.8) 0.17
Genotype 2/3, n (%) 185 107 (57.8) 78 (42.2)  
 Age, years 49 ± 12 48 ± 12 50 ± 11 0.16
 BMI (Kg/m2) 23.9 ± 2.7 24.3 ± 3.1 23.6 ± 2.4 0.16
 ALT (IU/L) 97 ± 94 101 ± 88 94 ± 88 0.51
 HCV RNA (IU/mL) 1.8×106±1.5×106 1.6×106±1.2×106 2.1×106±1.4×106 0.49
 F3-4 Fibrosis stage, n (%) 11/63 (17.5) 7/51 (13.7) 4/12 (33.3) 0.19
Genotype others, n (%) 9 (1.9) 6 (2.1) 3 (1.5)  
Propensity score matched patients Total PEG-IFN alfa-2a PEG-IFN alfa- 2b P*
Genotype 1, n (%) 248 124 124 0.45
 Age, years 50 ± 11 51 ± 11 50 ± 11 0.43
 Gender (male), n (%) 148 (59.7) 112 (65.5) 74 (64.3) 0.90
 BMI (Kg/m2) 24.4 ± 3.2 24.7 ± 3.2 24.3 ± 3.3 0.38
 ALT (IU/L) 93 ± 76 95 ± 74 92 ± 79 0.83
 HCV RNA (IU/mL) 3.0×106±1.3×106 2.5×106±1.3×106 3.6×106±1.1×106 0.31
 F3-4 Fibrosis stage, n (%) # 22/73 (30.1) 18/50 (36.0) 4/23 (18.2) 0.17
Genotype 2/3, n (%) 150 75 75  
 Age, years 50 ± 11 48 ± 12 50 ± 11 0.16
 Gender (male), n (%) 81 (54.0) 162 (61.8) 108 (62.1) 0.96
 BMI (Kg/m2) 23.9 ± 2.9 24.3 ± 3.1 23.6 ± 2.4 0.16
 ALT (IU/L) 89 ± 76 101 ± 88 94 ± 88 0.51
 HCV RNA (IU/mL) 1.7×106±1.4×106 1.6×106±1.2×106 2.1×106±1.4×106 0.49
F3-4 Fibrosis stage, n (%)§ 10/46 (21.7) 6/34 (17.6) 4/12 (33.3) 0.42
  1. Abbreviation: HCV, hepatitis C virus; BMI, body mass index; ALT, alanine aminotransferase; PEG-IFN, peginterferon.
  2. *P-value for difference between the PEG-IFN alfa-2a and PEG-IFN alfa-2b groups.
  3. mean ± standard deviation.
  4. §, ‡ Data were available only in 94 and 63 patients, respectively.
  5. #,¥Data were available only in 73 and 46 patients, respectively. If the number of patients was smaller than 5, Fisher’s exact test was used.